AR015983A1 - Ciertas 1(2-azanaftil)-4-(1-fenilmetil)piperazinas, ligandos de subtipos especificos de receptores de la dopamina - Google Patents
Ciertas 1(2-azanaftil)-4-(1-fenilmetil)piperazinas, ligandos de subtipos especificos de receptores de la dopaminaInfo
- Publication number
- AR015983A1 AR015983A1 ARP980105336A ARP980105336A AR015983A1 AR 015983 A1 AR015983 A1 AR 015983A1 AR P980105336 A ARP980105336 A AR P980105336A AR P980105336 A ARP980105336 A AR P980105336A AR 015983 A1 AR015983 A1 AR 015983A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- halogen
- represent
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un compuesto que comprende la formula (I) o las sales de adicion farmacéuticamente aceptables del mismo, donde X, Y y Z son iguales o diferentes yrepresentan CRc o nitrogeno;Rc representa hidrogeno,halogeno o alquilo C1-6; R1 y R2 representan independientemente hidrogeno, halogeno, hidroxi, alquilo C1-6,trifluorometilo, trifluorometoxi o SO2NH2, siempre que, cuando Y y Z representan CH y R3 y R4 representa hidrogeno en ambos casos, R1 y R2 no sean hidrogenosimultáneamente; o R1 y R2 juntos representan un grupo alquilendioxi C1-2 o un grupo alquilenoxi C1-3; R3 y R4 son iguales o diferentes y representanhidrogeno, halogeno, alquilo C1-6, alcoxi C1-4, alquiltio, hidroxi, amino, mono o dialquilamino donde cada alquilo es alquilo C1-6, ciano otrifluorometilo; Arepresenta alquileno C1-4; y R5, R6 y R7 representan independientemente hidrogeno o alquilo C1-6; que se ligan selectivamente con gran afinidad al subtipo D4de receptor de la dopamina y por lo tanto son utiles en el tratamiento y/oprevencion de diversos trastornos neuropsicologicos o afectivos, incluyendo, porejemplo la esquizofrenia, la manía, demencia, depresion, ansiedad, comportamiento compulsivo, abuso de sustancias, deterioro de la memoria, déficitscongnitivos, trastornos motores del tipo Parkinson, por ejemplo Parkinsonismo y distonía y trastornos motores relacionados con el uso de agentes neurolépticos.Estos compuestos son utiles en el tratamiento de la depresion, el deterioro de la memoria o la enfermedad de Alzheimer por medio de la modulacion de losreceptores D4 que existen selectivamente en el área límbica, de la cual se sabe que controla la emocion y las funciones cognitivas. Más aun, estos compuestosson utiles para el tratamiento de otros trastornos que responden al bloqueo dopaminérgico, por ejemplo el abuso de sustancias y el trastornoobsesivo-compulsivo. Estos compuestos también sirven para tratar los efectos secundarios extrapiramidales asociados con el uso de agentes neurolépticosconvencionales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95435397A | 1997-10-24 | 1997-10-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR015983A1 true AR015983A1 (es) | 2001-05-30 |
Family
ID=25495312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980105336A AR015983A1 (es) | 1997-10-24 | 1998-10-26 | Ciertas 1(2-azanaftil)-4-(1-fenilmetil)piperazinas, ligandos de subtipos especificos de receptores de la dopamina |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1025097B1 (es) |
| CN (1) | CN1191248C (es) |
| AR (1) | AR015983A1 (es) |
| AT (1) | ATE294173T1 (es) |
| AU (1) | AU9810498A (es) |
| CA (1) | CA2308057A1 (es) |
| CO (1) | CO4970840A1 (es) |
| DE (1) | DE69829989T2 (es) |
| ES (1) | ES2241172T3 (es) |
| WO (1) | WO1999021850A1 (es) |
| ZA (1) | ZA989720B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6040448A (en) * | 1997-10-24 | 2000-03-21 | Neurogen Corporation | Certain 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl) piperazines, dopamine receptor subtype specific ligands |
| AU6242999A (en) * | 1998-09-02 | 2000-03-21 | Neurogen Corporation | 2-aryl-4-(1-(4-heteroaryl)piperazin-1-yl) methylimidazoles: dopamine d4 receptor subtype ligands |
| EP1177792A3 (en) | 2000-07-27 | 2002-10-23 | Pfizer Products Inc. | Dopamine D4 Ligands for the treatment of novelty-seeking disorders |
| PE20060115A1 (es) | 2004-07-23 | 2006-03-23 | Basf Ag | 2-(piridin-2-il)-pirimidinas como agentes fungicidas |
| BRPI0609268A2 (pt) | 2005-03-31 | 2010-03-09 | Pfizer Prod Inc | derivados de ciclopentapiridina e tetraidroquinolina |
| JP4769866B2 (ja) | 2005-06-27 | 2011-09-07 | エフ．ホフマン−ラ ロシュ アーゲー | クロロ置換グアニジン |
| CN103992270B (zh) * | 2014-05-13 | 2016-06-08 | 泸州医学院 | 2-氯-5,6,7,8-四氢喹啉的制备方法 |
| EP3868752A1 (en) | 2014-08-28 | 2021-08-25 | Asceneuron SA | Glycosidase inhibitors |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| EP3419972B1 (en) | 2016-02-25 | 2023-07-26 | Asceneuron SA | Glycosidase inhibitors |
| MA43677A (fr) | 2016-02-25 | 2018-11-28 | Asceneuron Sa | Inhibiteurs de glycosidases |
| CN109071526B (zh) | 2016-02-25 | 2023-02-28 | 阿森纽荣股份公司 | 哌嗪衍生物的酸加成盐 |
| SG11201907774VA (en) | 2017-02-24 | 2019-09-27 | Asceneuron S A | Sulfoximine glycosidase inhibitors |
| WO2019037861A1 (en) | 2017-08-24 | 2019-02-28 | Asceneuron S.A. | ANNOTATED GLYCOSIDASE INHIBITORS |
| EP3672959A1 (en) | 2017-08-24 | 2020-07-01 | Asceneuron SA | Linear glycosidase inhibitors |
| WO2020039027A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Pyrrolidine glycosidase inhibitors |
| US11731972B2 (en) | 2018-08-22 | 2023-08-22 | Asceneuron Sa | Spiro compounds as glycosidase inhibitors |
| WO2020039028A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Tetrahydro-benzoazepine glycosidase inhibitors |
| WO2020169804A1 (en) | 2019-02-22 | 2020-08-27 | Asceneuron Sa | Fused glycosidase inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3576809A (en) * | 1968-05-06 | 1971-04-27 | Miles Lab | 2-substituted derivatives of 6-methoxyquinoline |
| US3629418A (en) * | 1969-02-14 | 1971-12-21 | Miles Lab | Process for producing an anti-depressant effect with piperazine quinolines |
| FI193974A (es) * | 1973-07-13 | 1975-01-14 | Merck & Co Inc | |
| US4091098A (en) * | 1977-04-25 | 1978-05-23 | Merck & Co., Inc. | 3-(1-PIPERAZINYL)-1,2,4-BENZOTRIAZINES AND N-oxides |
| DE2811312A1 (de) * | 1978-03-16 | 1979-09-27 | Hoechst Ag | Neue isochinolinderivate, verfahren zu ihrer herstellung und ihre verwendung zur herstellung von arzneimitteln |
| FR2692264B1 (fr) * | 1992-06-12 | 1994-08-05 | Adir | Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant. |
| FR2734819B1 (fr) * | 1995-05-31 | 1997-07-04 | Adir | Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant |
| US5859246A (en) * | 1997-01-30 | 1999-01-12 | Neurogen Corporation | 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands |
| NZ337183A (en) * | 1997-03-04 | 2001-05-25 | Neurogen Corp | 1-(isoquinolin-1-yl)-4-(1-phenylmethyl)piperazines; dopamine receptor subtype specific ligands useful for the treatment of psychotic disorders |
-
1998
- 1998-10-21 EP EP98952391A patent/EP1025097B1/en not_active Expired - Lifetime
- 1998-10-21 DE DE69829989T patent/DE69829989T2/de not_active Expired - Fee Related
- 1998-10-21 WO PCT/US1998/022233 patent/WO1999021850A1/en active IP Right Grant
- 1998-10-21 AT AT98952391T patent/ATE294173T1/de not_active IP Right Cessation
- 1998-10-21 CN CNB988126583A patent/CN1191248C/zh not_active Expired - Fee Related
- 1998-10-21 AU AU98104/98A patent/AU9810498A/en not_active Abandoned
- 1998-10-21 ES ES98952391T patent/ES2241172T3/es not_active Expired - Lifetime
- 1998-10-21 CA CA002308057A patent/CA2308057A1/en not_active Abandoned
- 1998-10-26 AR ARP980105336A patent/AR015983A1/es unknown
- 1998-10-26 CO CO98062496A patent/CO4970840A1/es unknown
- 1998-10-26 ZA ZA989720A patent/ZA989720B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1025097A1 (en) | 2000-08-09 |
| CN1283195A (zh) | 2001-02-07 |
| CA2308057A1 (en) | 1999-05-06 |
| EP1025097B1 (en) | 2005-04-27 |
| DE69829989D1 (en) | 2005-06-02 |
| ZA989720B (en) | 1999-04-26 |
| CN1191248C (zh) | 2005-03-02 |
| WO1999021850A1 (en) | 1999-05-06 |
| ATE294173T1 (de) | 2005-05-15 |
| ES2241172T3 (es) | 2005-10-16 |
| DE69829989T2 (de) | 2006-02-23 |
| AU9810498A (en) | 1999-05-17 |
| CO4970840A1 (es) | 2000-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR015983A1 (es) | Ciertas 1(2-azanaftil)-4-(1-fenilmetil)piperazinas, ligandos de subtipos especificos de receptores de la dopamina | |
| MX9702234A (es) | Ciertos derivados de aminometilfenilimidazol, una clase nueva de ligandos especificos del subtipo de receptor de dopamina. | |
| WO1992012134A3 (en) | Certain aminomethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands | |
| TR199902291T2 (xx) | �kame edilmi� 4-Arilmetilen-2-imino-2, 3-dihidrotiazoller | |
| ATE177099T1 (de) | Diazabicyclische neurokinin antagonisten | |
| ATE205493T1 (de) | N-aminoalkyldibenzofuran-carboxamide als dopaminrezeptor-subtyp spezifische liganden | |
| CY1108703T1 (el) | Αλλοστερικοι ρυθμιστες μεταβολοτροπων υποδοχεων γλουταμικου | |
| IS5352A (is) | Ný efnasambönd | |
| DE60024360D1 (de) | Verwendungen und Zusammensetzungen zur Behandlung von primären und sekundären Tumoren des Zentralnervensystems (ZNS) | |
| DE59510244D1 (de) | Substituierte pyrimidinverbindungen und deren verwendung | |
| DE69705035D1 (de) | N-Azacycloalkylalkyldibenzothiophencarboxamide: spezifische Liganden für Dopaminrezeptorsubtypen | |
| ATE297396T1 (de) | Neue atropisomere von 2,3-disubstituierten-(5,6)- heteroarylkondensierten-pyrimidin-4-onen | |
| BG105710A (en) | 5ht1 antagonists for antidepressant therapy | |
| DE69011054D1 (de) | Substituierte cyclohexene mit zentraler Nervensystem-Wirkung. | |
| AU2459897A (en) | Novel n-aminoalkyl-1-biphenylenyl-2-carboxamides; new dopamine receptor subtype specific ligands | |
| ATE373475T1 (de) | Carbamate von 2-heterozyklischen 1,2-ethandiolen | |
| DE69824670D1 (de) | TCF-II für Vorbeugung und/oder Behandlung von strahlungsinduzierter Störungen | |
| BR9909878A (pt) | 10-canfosulfonato de paroxetina para tratamento de distúrbios do sistema nervoso central | |
| DK0987269T3 (da) | Salte af optisk aktivt sulfoxidderivat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |